NCI Trials for Oct. 2020

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase I – 10410

A Phase 1 Study of IPdR in Combination with Capecitabine and Radiotherapy in Rectal Cancer

University Health Network Princess Margaret Cancer Center LAO

Kinsella, Timothy James

(401) 444-6203


Phase II – 10398

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma

National Cancer Institute LAO

Chen, A P

(240) 781-3320


Phase II – S2000

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases

SWOG

Eroglu, Zeynep

(813) 745-8581


Phase II/III – EA2197

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

ECOG-ACRIN Cancer Research Group

Maithel, Shishir Kumar

(404) 617-7936


Phase III – EA2176

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-NaÔve Metastatic Anal Cancer Patients

ECOG-ACRIN Cancer Research Group

Eng, Cathy

615-936-0809


Phase III – EA5182

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

ECOG-ACRIN Cancer Research Group

Yu, Helena A.

(646) 888-4274


Phase III – NRG-HN007

An Open-Label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NRG Oncology

Ma, Brigette Buig-Yue

852- 35052118


Phase Other – 10323

Cancer Moonshot Biobank Research Protocol

Division of Cancer Treatment and Diagnosis

Moore, Helen M.

(240) 276-5713

Table of Contents

YOU MAY BE INTERESTED IN

With growing evidence that molecular characterization of a tumor helps predict a patient’s prognosis and response to specific treatments, biomarker testing has been required or recommended for more than half of the 62 oncology drugs introduced over the past five years. However, health insurance policies don’t always cover tests, thus denying their clients access to precision medicine.
Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).

Login